Is Buying Stock Like Alnylam Pharmaceuticals, Inc. (ALNY) After This Double Top Chart Pattern a Winning Strategy?

December 12, 2017 - By Nellie Frank

Investors sentiment increased to 1.52 in Q2 2017. Its up 0.70, from 0.82 in 2017Q1. It increased, as 24 investors sold Alnylam Pharmaceuticals, Inc. shares while 49 reduced holdings. 49 funds opened positions while 62 raised stakes. 85.40 million shares or 6.40% more from 80.26 million shares in 2017Q1 were reported.
Gotham Asset Mngmt Lc holds 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 9,684 shares. Orbimed Advsr Ltd Com reported 0.53% stake. Rockefeller Fincl Inc reported 332,058 shares. Ckw Fincl invested in 0.01% or 500 shares. Tortoise Management Limited Liability Com owns 198 shares for 0.01% of their portfolio. Pdts Ltd Liability owns 295,100 shares or 0.95% of their US portfolio. Point72 Asset Management Limited Partnership has 50,000 shares for 0.02% of their portfolio. Morgan Stanley holds 0.02% or 1.02 million shares in its portfolio. Winslow Evans Crocker has 1,435 shares for 0% of their portfolio. State Board Of Administration Of Florida Retirement Systems holds 108,708 shares. 508,852 were accumulated by Tiaa Cref Management Ltd Liability Co. Bradley Foster And Sargent Ct owns 4,115 shares or 0.01% of their US portfolio. 91,222 are held by Rhumbline Advisers. Meeder Asset Mgmt reported 0% stake. Tocqueville Asset Ltd Partnership has 16,575 shares for 0.02% of their portfolio.

The chart of Alnylam Pharmaceuticals, Inc. (ALNY) shows a double top with $135.88 target or 7.00 % above today’s $126.99 share price. The 6 months chart pattern indicates low risk for the $12.59 billion company. It was reported on Dec, 12 by If the $135.88 price target is reached, the company will be worth $881.58M more. Double tops are rare but powerful chart patterns.

The stock decreased 0.94% or $1.21 during the last trading session, reaching $126.99. About 382,410 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since December 12, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 14. They expect $-1.36 earnings per share, down 3.03 % or $0.04 from last year’s $-1.32 per share. After $-1.34 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.49 % negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 85 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies reinitiated Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, June 22. Jefferies has “Buy” rating and $10200 target. Piper Jaffray maintained it with “Buy” rating and $110.0 target in Wednesday, September 20 report. BMO Capital Markets maintained it with “Buy” rating and $168.0 target in Wednesday, November 8 report. Needham maintained the stock with “Buy” rating in Wednesday, November 16 report. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Chardan Capital Markets on Thursday, October 6. On Tuesday, July 11 the stock rating was maintained by Cowen & Co with “Buy”. On Thursday, September 21 the stock rating was maintained by Needham with “Buy”. The firm has “Overweight” rating by Barclays Capital given on Wednesday, November 8. The company was initiated on Friday, October 23 by Jefferies. The rating was maintained by Jefferies with “Buy” on Monday, September 25.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: which released: “Alnylam Pharmaceuticals Announces Proposed Public Offering of $675000000 of …” on November 13, 2017, also with their article: “Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock …” published on November 16, 2017, published: “Alnylam Pharma (ALNY) Completes Submission of NDA to FDA for Patisiran for …” on December 12, 2017. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: and their article: “Alnylam Sets Its Eyes On The Finish Line” published on November 20, 2017 as well as‘s news article titled: “Why Alnylam Pharmaceuticals Rose 12.7% in November” with publication date: December 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: